8-K: Marker Therapeutics Secures $9.5 Million Grant to Advance Pancreatic Cancer Therapy

Marker Therapeutics has been awarded a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support clinical trials of its MT-601 therapy for pancreatic cancer.

Summary

• Marker Therapeutics has received a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT).
• The grant will fund a Phase 1 clinical trial of MT-601 in patients with metastatic pancreatic cancer.
• MT-601 is a multi-tumor associated antigen (multiTAA)-specific T cell product.
• The company's lead asset, MT-601, is also being studied in patients with relapsed lymphoma.
• Previous studies of multiTAA-specific T cells in pancreatic cancer showed a favorable safety profile and durable cancer control, including 1 complete response, 3 partial responses and 6 patients with stable disease.
• The company has received over $30 million in non-dilutive funding from governmental institutions, including a recent $2 million grant from the NIH.
• Marker Therapeutics anticipates initiating the clinical program for MT-601 in pancreatic cancer in 2025.

Sentiment

Score: 8

Explanation: The document is positive due to the significant grant funding, promising early clinical data, and the potential of the company's technology. The company is also receiving non-dilutive funding which is a positive sign.

Positives

• The $9.5 million grant from CPRIT provides significant non-dilutive funding for the pancreatic cancer program.
• The company has secured a total of over $30 million in non-dilutive funding from governmental institutions.
• Previous studies of multiTAA-specific T cells in pancreatic cancer showed promising results, including durable cancer control and tumor responses.
• The company's multiTAA-specific T cell platform is non-genetically modified, potentially leading to easier and less expensive manufacturing.
• The broad target recognition profile of MT-601 allows for potential application in multiple cancer indications.

Risks

• The success of the clinical trials for MT-601 is not guaranteed.
• The company is still in the clinical stage and has not yet brought a product to market.
• The company's future success depends on the ability to secure additional funding and achieve regulatory approvals.

Future Outlook

Marker Therapeutics anticipates initiating the clinical program for MT-601 in pancreatic cancer in 2025.

Management Comments

• Juan Vera, M.D., President and CEO of Marker Therapeutics, stated that the CPRIT grant underscores the innovation behind their therapy and recognizes the potential impact of their study.
• Dr. Vera also noted that the grants from CPRIT and NIH will allow them to advance MT-601 in pancreatic cancer without affecting operations in the ongoing study of MT-601 in patients with lymphoma.

Industry Context

The announcement highlights the growing interest in T cell-based immunotherapies for cancer treatment, particularly in solid tumors like pancreatic cancer, which have historically been difficult to treat. The company is leveraging non-genetically modified T-cell technology which is a growing area of interest in the industry.

Comparison to Industry Standards

• The company's multiTAA-specific T cell approach is differentiated from CAR-T cell therapies, which are genetically engineered and target a single antigen.
• The company's approach is similar to other companies developing multi-antigen T-cell therapies, such as Adaptimmune and Immatics, but the company's approach is non-genetically modified.
• The company's previous study results in pancreatic cancer, with 1 complete response, 3 partial responses and 6 patients with stable disease, are comparable to other early-stage clinical trials in the field.
• The company's ability to secure non-dilutive funding from government institutions is a positive sign of the potential of their technology.

Stakeholder Impact

• Shareholders will likely view the grant as a positive development, potentially increasing the company's valuation.
• Employees may be encouraged by the company's progress and the additional funding.
• Patients with pancreatic cancer may benefit from the development of a new treatment option.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The company will initiate a Phase 1 clinical trial of MT-601 in patients with metastatic pancreatic cancer in 2025.
• The company will continue to advance the ongoing study of MT-601 in patients with lymphoma.

Key Dates

Keywords

Marker Therapeutics, MT-601, pancreatic cancer, immunotherapy, T cell therapy, CPRIT, clinical trial, multiTAA, non-dilutive funding, oncology